References:

Aogi K et al. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: Efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 2011;129(3):829-38. Abstract

Aogi K et al. The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype. Cancer Chemother Pharmacol 2011;67(5):1007-15. Abstract

Brufsky A et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: Subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat 2012;[Epub ahead of print]. Abstract

Brufsky AM et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011;29(32):4286-93. Abstract

Cortes J et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis. Ann Oncol 2012;23(5):1130-7. Abstract

Miller KD et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23(4):792-9. Abstract

Oostendorp LJ et al. Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: A systematic review. Lancet Oncol 2011;12(11):1053-61. Abstract

Pierga JY et al. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004;88(2):117-29. Abstract

Von Minckwitz G et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med 2012;366(4):299-309. Abstract